DFDA

Clinical Trials for Alzheimer's Disease

Focusing on: Rivastigmine

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Specify a medical condition you are interested in.

Specify a drug, device, or procedure if you are looking for trials for a specific intervention.

Displaying 10 of 55 results.

Page 1 of 6
Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia
Completed
Interventions:ENA713
Study Type: INTERVENTIONAL
Phase: PHASE4
Enrollment: 121
Age: 50 Years - 85 Years
Gender: ALL
Locations: Novartis Investigative Site; Novartis Investigative Site; +2 more
Has Results
View Study Details
Brain Changes by Rivastigmine According to Butyrylcholinesterase Alleles
UnknownLast Known: ACTIVE_NOT_RECRUITING
Interventions:Rivastigmine
Study Type: INTERVENTIONAL
Phase: NA
Enrollment: 70
Age: 55 Years - 80 Years
Gender: ALL
Locations: Seoul Metropolitan Government Seoul National University Boramae Medical Center
View Study Details
A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.
Completed
Interventions:Rivastigmine
Study Type: INTERVENTIONAL
Phase: PHASE4
Enrollment: 100
Age: N/A
Gender: ALL
Locations: Novartis Investigative Site; Novartis Investigative Site; +7 more
Has Results
View Study Details
A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
Completed
Study Type: INTERVENTIONAL
Phase: PHASE3
Enrollment: 501
Age: 50 Years - 85 Years
Gender: ALL
Locations: Novartis Investigative Site; Novartis Investigative Site; +14 more
Has Results
View Study Details
Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients
Completed
Interventions:Rivastigmine patch
Study Type: OBSERVATIONAL
Phase: N/A
Enrollment: 300
Age: 51 Years - 85 Years
Gender: ALL
Locations: Dong-A University Hospital; Pusan National University Hospital; +17 more
View Study Details
A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease
Completed
Study Type: INTERVENTIONAL
Phase: PHASE4
Enrollment: 51
Age: From 50 Years
Gender: ALL
Locations: Novartis Investigative Site; Novartis Investigational Site; +3 more
View Study Details
Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine
Completed
Interventions:rivastigmine patch
Study Type: INTERVENTIONAL
Phase: NA
Enrollment: 300
Age: 50 Years - 90 Years
Gender: ALL
Locations: Holy Family Hospital, The Catholic Univerisy of Korea, School of Medicine; Busan National University Hospital; +14 more
View Study Details
Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease
Completed
Interventions:Rivastigmine
Study Type: INTERVENTIONAL
Phase: PHASE4
Enrollment: 80
Age: 50 Years - 85 Years
Gender: ALL
Locations: Novartis Pharmaceuticals
View Study Details
16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients
Completed
Interventions:ENA713
Study Type: INTERVENTIONAL
Phase: PHASE4
Enrollment: 222
Age: 50 Years - 85 Years
Gender: ALL
Locations: Novartis Investigative Site
Has Results
View Study Details
A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)
Completed
Study Type: INTERVENTIONAL
Phase: PHASE4
Enrollment: 228
Age: From 50 Years
Gender: ALL
Locations: Novartis Investigative Site
Has Results
View Study Details